Zixing Wang
Research Subjects
Zixing Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Bot
Capstan Therapeutics, San Diego, California
7 shared publications - Carmen M. Warren
Kite, a Gilead Company, Santa Monica, California
7 shared publications - Christina To
Kite, a Gilead Company, Santa Monica, California
7 shared publications - Craig A. Portell
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Department of Medicine, Charlottesville, USA
7 shared publications - Ethan G. Aguilar
Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA
7 shared publications - Jason R. Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
7 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 28 December 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 23 (3) , 325-338
Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard
With the advent of cancer immunotherapy, some special features including delayed treatment effect, cure rate, diminishing treatment effect and crossing survival are often observed in survival analysis. They violate the proportional hazard model assumption and pose a unique challenge for the conventional trial design and analysis strategies. Many methods like cure rate model have been developed based on mixture model to incorporate some of these features. In this work, we extend the mixture model to deal with multiple non‐proportional patterns and develop its geometric average hazard ratio (gAHR) to quantify the treatment effect. We further derive a sample size and power formula based on the non‐centrality parameter of the log‐rank test and conduct a thorough analysis of the impact of each parameter on performance. Simulation studies showed a clear advantage of our new method over the proportional hazard based calculation across different non‐proportional hazard scenarios. Moreover, the mixture modeling of two real trials demonstrates how to use the prior information on the survival distribution among patients with different biomarker and early efficacy results in practice. By comparison with a simulation‐based design, the new method provided a more efficient way to compute the power and sample size with high accuracy of estimation. Overall, both theoretical derivation and empirical studies demonstrate the promise of the proposed method in powering future innovative trial designs.
- 28 December 2023
- Published by Wiley in Pharmaceutical Statistics
- Vol. 23 (3) , 325-338
Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard
With the advent of cancer immunotherapy, some special features including delayed treatment effect, cure rate, diminishing treatment effect and crossing survival are often observed in survival analysis. They violate the proportional hazard model assumption and pose a unique challenge for the conventional trial design and analysis strategies. Many methods like cure rate model have been developed based on mixture model to incorporate some of these features. In this work, we extend the mixture model to deal with multiple non‐proportional patterns and develop its geometric average hazard ratio (gAHR) to quantify the treatment effect. We further derive a sample size and power formula based on the non‐centrality parameter of the log‐rank test and conduct a thorough analysis of the impact of each parameter on performance. Simulation studies showed a clear advantage of our new method over the proportional hazard based calculation across different non‐proportional hazard scenarios. Moreover, the mixture modeling of two real trials demonstrates how to use the prior information on the survival distribution among patients with different biomarker and early efficacy results in practice. By comparison with a simulation‐based design, the new method provided a more efficient way to compute the power and sample size with high accuracy of estimation. Overall, both theoretical derivation and empirical studies demonstrate the promise of the proposed method in powering future innovative trial designs.
- Open Access
- 17 November 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (1) , 21-33
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products. Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed. This article is featured in Selected Articles from This Issue, p. 4
- 17 November 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (1) , 21-33
Open AccessProduct Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products. Significance: In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed. This article is featured in Selected Articles from This Issue, p. 4